论文部分内容阅读
目的检测Ki-67蛋白在乳腺癌组织中的表达,及其与乳腺癌肿瘤病理核分裂像计数、淋巴结转移、临床病理学指标间的关系。方法采用免疫组织化学技术检测乳腺癌组织中Ki-67蛋白的表达,分析阳性表达与乳腺癌病理核分裂像计数、腋窝淋巴结转移、雌激素受体(ER)和孕激素受体(PR)、人表皮生长因子受体-2(HER-2)表达之间的关系。结果 Ki-67蛋白在乳腺癌病理核分裂像计数的表达与恶性程度具有显著的相关性;Ki-67蛋白在ER和PR阳性组中表达显著低于ER和PR阴性组,而在HER-2阳性组中表达显著高于HER-2阴性组。结论 Ki-67可作为判断乳腺癌患者预后及疗效的重要标志物,同时联合检测Ki-67和其他乳腺癌病理学指标有助于了解乳腺癌生物学行为,为治疗和预后提供思路。
Objective To detect the expression of Ki-67 protein in breast cancer and its relationship with the pathological score of mitosis, lymph node metastasis and clinicopathological parameters in breast cancer. Methods Immunohistochemical technique was used to detect the expression of Ki-67 in breast cancer tissues. The positive expression of Ki-67 protein in breast cancer tissues was analyzed with pathological mitosis, axillary lymph node metastasis, estrogen receptor (ER) and progesterone receptor (PR) Relationship between the expression of epidermal growth factor receptor-2 (HER-2). Results The expression of Ki-67 protein in breast cancer was significantly correlated with the degree of malignancy. The expression of Ki-67 protein in ER and PR positive groups was significantly lower than that in ER and PR negative groups, while in HER-2 positive The expression in the group was significantly higher than that in the HER-2 negative group. Conclusions Ki-67 can be used as an important marker in predicting the prognosis and efficacy of breast cancer patients. Combined detection of Ki-67 and other pathological markers of breast cancer will help to understand the biological behavior of breast cancer and provide ideas for the treatment and prognosis.